Blockchain Registration Transaction Record

Kairos Pharma Receives $876K DoD Award for ENV105 Trial Research

Kairos Pharma receives funding from the U.S. Department of Defense for biomarker research in non-small cell lung cancer, highlighting the company's commitment to improving outcomes through targeted therapy. ENV105, the lead candidate, is being studied in Phase 1 and 2 trials for lung cancer and prostate cancer, addressing critical unmet medical needs.

This news highlights the innovative research being conducted by Kairos Pharma to address drug resistance in cancer treatment, potentially leading to improved outcomes for patients with non-small cell lung cancer and prostate cancer. The funding from the U.S. Department of Defense underscores the importance of precision medicine in developing targeted therapies for patients with specific genetic mutations.